Q-omics provides the consensus-scored RFTN1P1 profile across patient tissues and cancer cell-line models. RFTN1P1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RFTN1P1 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, RFTN1P1 RNA expression shows 5,357 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, LUAD, and STAD as cancer lineages where RFTN1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFTN1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFTN1P1 survival associations across molecular data types. RFTN1P1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFTN1P1 RNA expression–survival associations across cancer types. High RFTN1P1 expression shows unfavorable associations in KIRP, LIHC, PAAD, OV and LUAD, but favorable associations in PRAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify KIRP as the clearest survival context for RFTN1P1 RNA expression.
This table summarizes RFTN1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RFTN1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFTN1P1 shows lower tumor expression in LUAD and KIRC. The LUAD box plot shows higher RFTN1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.208, t-test p = .002).
This table shows molecular features associated with RFTN1P1 in patient tissues and cancer cell lines. In patient samples, RFTN1P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
